Pathophysiology and current management of pruritus in liver disease

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 2, 2011, Pages 89-97

  Kremer, Andreas E ^a   Oude Elferink, Ronald P J ^a   Beuers, Ulrich ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; HISTAMINE; LYSOPHOSPHATIDIC ACID; NALTREXONE; OPIATE; PLACEBO; PROGESTERONE; RIFAMPICIN; SEROTONIN; SERTRALINE; STEROID HORMONE; URSODEOXYCHOLIC ACID;

ABDOMINAL DISCOMFORT; BLEEDING; BLOATING; CHOLESTASIS; CLINICAL FEATURE; DIARRHEA; DISEASE ASSOCIATION; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER DISEASE; LIVER TOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; RECOMMENDED DRUG DOSE; SHORT SURVEY;

EID: 80052338886     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2010.10.007     Document Type: Short Survey

References (139)

1. Adams F. The extant works of Aretaeus, the Cappadocian. Chapter XV. On Jaundice or Icterus. London: Sydenham Society; 1865. p. 324-8.
2. Beuers U, Boberg KM, Chapman RW, Chazouilleres O, Invernizzi P, Jones DE, et al. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
3. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009;50:291-308.
4. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005-13.
5. Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008;68:2163-82.
6. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009;15:2049-66.
7. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973;289:674-8.
8. James O, Macklon AF, Watson AJ. Primary biliary cirrhosis - a revised clinical spectrum. Lancet 1981;1:1278-81.
9. Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000;14:643-55.
10. Koulentaki M, Ioannidou D, Stefanidou M, Maraki S, Drigiannakis I, Dimoulios P, et al. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 2006;101:541-6.
11. McPhedran NT, Henderson RD. Pruritus and jaundice. Can Med Assoc J 1965;92:1258-60.
12. Cribier B, Samain F, Vetter D, Heid E, Grosshans E. Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol 1998;78:355-7.
13. Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, Di Bisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998;43:2177-83.
14. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. Multidepartment virus C. Arthritis Rheum 1999;42:2204-12.
15. Ghent CN, Bloomer JR. Itch in liver disease: facts and speculations. Yale J Biol Med 1979;52:77-82.
16. Elias E, Burra P. Primary biliary cirrhosis: symptomatic treatment. J Gastroenterol Hepatol 1991;6:570-3.
17. Elias E. Liver transplantation. J R Coll Phys Lond 1993;27:224-32.
18. Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contra-indicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001;13:1393-4.
19. Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.World J Gastroenterol 2006;12:3487-95.
20. Swain MG. Pruritus and lethargy in the primary billary cirrhosis patient. In: Neuberger J, editor. Primary biliary cirrhosis. Eastbourne: West End Studios; 1999. p. 75-81.
21. Varco RL. Intermittent external biliary drainage for relief of pruritus in certain chronic disorders of the liver. Surgery 1947;21:43-5.
22. Huet PM, Rautureau M, Dhumeaux D, Caroli J. The effects of biliary drainage in cholestatic hepatitis. Rev Med Chir Mal Foie 1970;45:271-8.
23. Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002;35:1501-6.
24. Stapelbroek JM, van Erpecum KJ, Klomp LW, Venneman NG, Schwartz TP, van Berge Henegouwen GP, et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006;43:51-3.
25. Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006;44:280-1.
26. Singh V, Bhalla A, Sharma N, Dheerendra PC, Agarwal R, Mahi SK. Nasobiliary drainage in acute cholestatic hepatitis with pruritus. Dig Liver Dis 2009;41:442-5.
27. Mann WN. Biliary cirrhosis: an appraisal. The Croonian Lecture 1975. J R Coll Physicians Lond 1976;10:117-32.
28. Budd G. On jaundice. Chapter V. On diseases of the liver. London: John Churchill; 1845. p. 372-88.
29. Beuers U, Boyer JL. Bile - A historical review of studies on its form and function. In: Kirsner JB, editor. Gastroenterology in the 20th century. New York: Lea & Ferbiger; 1994. p. 267-88.
30. Frerichs FT. On jaundice. Chapter V. On diseases of the liver. London: John Churchill; 1845. p. 372-88.
31. Carey Jr JB. Bile acids in the serum of jaundiced patients. Gastroenterology 1961;41:285-7.
32. Ahrens Jr EH, Payne MA, Kunkel HG, Eisenmenger WJ, Blondheim SH. Primary biliary cirrhosis. Medicine (Baltimore) 1950;29:299-364.
33. Ricci P, Hofmann AF, Hagey LR, Jorgensen RA, Rolland Dickson E, Lindor KD. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig Dis Sci 1998;43:1292-5.
34. Kirby J, Heaton KW, Burton JL. Pruritic effect of bile salts. Br Med J 1974;4:693-5.
35. Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974;109:678-81.
36. Van Itallie TB, Hashim SA, Crampton RS, Tennent DM. The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine. N Engl J Med 1961;265:469-74.
37. Carey Jr JB, Williams G. Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA 1961;176:432-5.
38. Oster ZH, Rachmilewitz EA, Moran E, Stein Y. Relief of pruritus by cholestyramine in chronic liver disease. Isr J Med Sci 1965;1:599-606.
39. Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966;50:323-32.
40. Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, Loretde-Mola O, Nahmad M, Burnweit CA. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998;33:220-4.
41. Rupp N. Indications and results of percutaneous transhepatic bile-duct drainage. Chirurgie 1979;50:233-8.
42. Hall RI, Denyer ME, Chapman AH. Percutaneous-endoscopic placement of endoprostheses for relief of jaundice caused by inoperable bile duct strictures. Surgery 1990;107:224-7.
43. Robson PC, Heffernan N, Gonen M, Thornton R, Brody LA, Holmes R, et al. Prospective study of outcomes after percutaneous biliary drainage for malignant biliary obstruction. Ann Surg Oncol 2010;17:2303-11.
44. Mamianetti A, Tripodi V, Vescina C, Garrido D, Vizioli N, Carducci C, et al. Serum bile acids and pruritus in hemodialysis patients. Clin Nephrol 2000;53:194-8.
45. Jimenez F, Monte MJ, El-Mir MY, Pascual MJ, Marin JJ. Chronic renal failure-induced changes in serum and urine bile acid profiles. Dig Dis Sci 2002;47:2398-406.
46. Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 2000;14:33-40.
47. Sinakos E, Lindor KD. Bile acid profiles in intrahepatic cholestasis of pregnancy: is this the solution to the enigma of intrahepatic cholestasis of pregnancy? Am J Gastroenterol 2010;105:596-8.
48. Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology 1977;73:1125-30.
49. Freedman MR, Holzbach RT, Ferguson DR. Pruritus in cholestasis: no direct causative role for bile acid retention. Am J Med 1981;70:1011-6.
50. Bartholomew TC, Summerfield JA, Billing BH, Lawson AM, Setchell KD. Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry. Clin Sci (Lond) 1982;63:65-73.
51. Kremer AE, Martens JJ, Kulik W, Rueff F, Kuiper EM, van Buuren HR, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010;139:1008-18.
52. Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut 1972;13:201-6.
53. Chanarin I, Szur L. Letter: relief of intractable pruritis in polycythaemia rubra vera with cholestyramine. Br J Haematol 1975;29:669-70.
54. Kuiper EM, van Erpecum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:1334-40.
55. Ghent CN, Bloomer JR, Hsia YE. Efficacy and safety of longterm phenobarbital therapy of familial cholestasis. J Pediatr 1978;93:127-32.
56. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988;94:488-93.
57. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of longterm rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102:2077-80.
58. Osborn EC, Wootton ID, da SL, Sherlock S. Serum-bile-acid levels in liver disease. Lancet 1959;2:1049-53.
59. Alva J, Iber FL. Relief of the pruritus of jaundice with methandrostenolone and speculations on the nature of pruritus in liver disease. Am J Med Sci 1965;250:60-5.
60. Chen SC, Wu FS. Mechanism underlying inhibition of the capsaicin receptor-mediated current by pregnenolone sulfate in rat dorsal root ganglion neurons. Brain Res 2004;1027:196-200.
61. Park-Chung M, Malayev A, Purdy RH, Gibbs TT, Farb DH. Sulfated and unsulfated steroids modulate gamma-aminobutyric acid. A receptor function through distinct sites. Brain Res 1999;830:72-87.
62. Wu FS, Gibbs TT, Farb DH. Inverse modulation of gammaaminobutyric acid - and glycine-induced currents by progesterone. Mol Pharmacol 1990;37:597-602.
63. Park-Chung M, Wu FS, Purdy RH, Malayev AA, Gibbs TT, Farb DH. Distinct sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated steroids. Mol Pharmacol 1997;52:1113-23.
64. Weaver Jr CE, Marek P, Park-Chung M, Tam SW, Farb DH. Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997;94:10450-4.
65. Weaver Jr CE, Park-Chung M, Gibbs TT, Farb DH. 17 beta-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res 1997;761:338-41.
66. Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999;22:410-6.
67. Wetzel CH, Hermann B, Behl C, Pestel E, Rammes G, Zieglgansberger W, et al. Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol Endocrinol 1998;12:1441-51.
68. Green AD, Young KK, Lehto SG, Smith SB, Mogil JS. Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse. Pain 2006;124:50-8.
69. Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in men. Gut 1986;27:1373-6.
70. Kancheva R, Hill M, Cibula D, Vcelakova H, Kancheva L, Vrbikova J, et al. Relationships of circulating pregnanolone isomers and their polar conjugates to the status of sex, menstrual cycle, and pregnancy. J Endocrinol 2007;195:67-78.
71. Reyes H, Sjovall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med 2000;32:94-106.
72. Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007;2:26.
73. Glantz A, Reilly SJ, Benthin L, Lammert F, Mattsson LA, Marschall HU. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 2008;47:544-51.
74. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990;11:884-7.
75. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988;33:149-60.
76. Thomas DA, Williams GM, Iwata K, Kenshalo Jr DR, Dubner R. Effects of central administration of opioids on facial scratching in monkeys. Brain Res 1992;585:315-7.
77. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992;103:630-5.
78. Bergasa NV, Vergalla J, Swain MG, Jones EA. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996;16:298-302.
79. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988;297:1501-4.
80. Spivey JR, Jorgensen RA, Gores GJ, Lindor KD. Methionineenkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 1994;89:2028-32.
81. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993;53:1253-7.
82. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1992;15:220-4.
83. Bergasa NV, Sabol SL, Young 3rd WS, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995;268:G346-54.
84. Bergasa NV, Liau S, Homel P, Ghali V. Hepatic met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002;22:107-13.
85. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-9.
86. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995;123:161-7.
87. Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996;91:1022-3.
88. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-9.
89. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27:679-84.
90. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22.
91. Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006;12:1125-8.
92. Summerfield JA. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol 1980;10:180-3.
93. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999;29:1003-6.
94. Nelson L, Vergnolle N, D'Mello C, Chapman K, Le T, Swain MG. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol 2006;44:1141-9.
95. Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut 1990;31:96-9.
96. Clements WD, O'Rourke DM, Rowlands BJ, Ennis M. The role of mast cell activation in cholestatic pruritus. Agents Actions 1994;41(Spec No.):C30-1.
97. Quist RG, Ton-Nu HT, Lillienau J, Hofmann AF, Barrett KE. Activation of mast cells by bile acids. Gastroenterology 1991;101:446-56.
98. Rioux KP, Sharkey KA, Wallace JL, Swain MG. Hepatic mucosal mast cell hyperplasia in rats with secondary biliary cirrhosis. Hepatology 1996;23:888-95.
99. Inagaki N, Nagao M, Igeta K, Kawasaki H, Kim JF, Nagai H. Scratching behavior in various strains of mice. Skin Pharmacol Appl Skin Physiol 2001;14:87-96.
100. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch sensation. Science 2009;325:1531-4.
101. Hagermark O. Peripheral and central mediators of itch. Skin Pharmacol 1992;5:1-8.
102. Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? Inflamm Res 1997;46:412-6.
103. Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98:2736-41.
104. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007;45:666-74.
105. Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003;26:1105-12.
106. Schworer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993;341:1277.
107. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7.
108. O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005;21:1041-5.
109. Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology 2007;54:1196-9.
110. Hashimoto T, Ohata H, Momose K. Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology 2004;72:51-6.
111. Kremer AE, Martens JJ, Kulik W, Williamson C, Moolenaar WH, Kondrackiene J, et al. Autotaxin but not bile salts correlate with itch intensity in cholestasis. J Hepatol 2010;52:S1.
112. Balistreri WF, Heubi JE, Whitington P, et al. Ursodeoxycholic acid (UDCA) therapy in pediatric hepatobiliary disease. Hepatology 1989;10:602A.
113. Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998;26:49-55.
114. Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk J Pediatr 1999;41:91-8.
115. Lindor KD, Mayo primary sclerosing cholangitisursodeoxycholic acid study group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-5.
116. Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003;1:297-302.
117. Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997;27:1022-8.
118. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005;129:894-901.
119. Datta DV, Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J 1963;1:216-9.
120. Di Padova C, Tritapepe R, Rovagnati P, Rossetti S. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984;6:773-6.
121. Duncan JS, Kennedy HJ, Triger DR. Treatment of pruritus due to chronic obstructive liver disease. Br Med J (Clin Res Ed) 1984;289:22.
122. Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol 2005;28:147-57.
123. Rust C, Sauter GH, Oswald M, Buttner J, Kullak-Ublick GA, Paumgartner G, et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 2000;30:135-9.
124. LeCluyse EL. Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 2001;134:283-9.
125. Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005;129:476-85.
126. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;1:574-6.
127. Podesta A, Lopez P, Terg R, Villamil F, Flores D, Mastai R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991;36:216-20.
128. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002;50:436-9.
129. Borgeat A, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993;104:244-7.
130. Villamil AG, Bandi JC, Galdame OA, Gerona S, Gadano AC. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med 2005;118:1160-3.
131. Turner IB, Rawlins MD, Wood P, James OF. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther 1994;8:337-42.
132. Walt RP, Daneshmend TK, Fellows IW, Toghill PJ. Effect of stanozolol on itching in primary biliary cirrhosis. Br Med J (Clin Res Ed) 1988;296:607.
133. Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002;97:2117-9.
134. Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am 2006;35:113-23.
135. Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985;26:291-4.
136. Macia M, Aviles J, Navarro J, Morales S, Garcia J. Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med 2003;114:62-4.
137. Pares A, Cisneros L, Salmeron JM, Caballeria L, Mas A, Torras A, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004;99: 1105-10.
138. Pares A, Herrera M, Aviles J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010;53:307-12.
139. Pusl T, Denk GU, Parhofer KG, Beuers U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006;45:887-91.